Two Sigma Investments’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-14,549
Closed -$23.1K 3338
2023
Q1
$23.1K Sell
14,549
-45,225
-76% -$82.2K ﹤0.01% 2840
2022
Q4
$87.3K Buy
+59,774
New +$175K ﹤0.01% 2524
2022
Q1
Sell
-159,331
Closed -$582K 4585
2021
Q4
$582K Buy
+159,331
New +$850K ﹤0.01% 3101
2020
Q1
Sell
-12,790
Closed -$151K 3950
2019
Q4
$151K Buy
12,790
+10,143
+383% +$170K ﹤0.01% 3474
2019
Q3
$67K Sell
2,647
-1,755
-40% -$50.6K ﹤0.01% 3340
2019
Q2
$112K Buy
+4,402
New +$170K ﹤0.01% 3189
2019
Q1
Sell
-1,032
Closed -$15K 3544
2018
Q4
$15K Sell
1,032
-1,034
-50% -$42.2K ﹤0.01% 2894
2018
Q3
$145K Sell
2,066
-934
-31% -$70.9K ﹤0.01% 3052
2018
Q2
$223K Buy
3,000
+2,445
+441% +$218K ﹤0.01% 3091
2018
Q1
$53K Buy
+555
New +$95.2K ﹤0.01% 3064
2015
Q1
Sell
-85
Closed -$46K 2908
2014
Q4
$46K Sell
85
-757
-90% -$341K ﹤0.01% 2166
2014
Q3
$1.26M Buy
842
+787
+1,431% +$1.14M 0.01% 1002
2014
Q2
$76K Buy
+55
New +$63.8K ﹤0.01% 2067
2014
Q1
Sell
-91
Closed -$90K 2313
2013
Q4
$90K Buy
+91
New +$94.1K ﹤0.01% 2090

Other funds holding VIRX

Two Sigma Investments's VIRX Position: Q2 2023 in Review

Two Sigma Investments sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 14,549 shares — an estimated $23.1K sold.

Two Sigma Investments first reported a position in VIRX in Q4 2013 and held it in 14 quarters. The position peaked at $1.26M in Q3 2014. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

  • Two Sigma Investments reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Investments sold 14,549 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $23.1K.
  • Two Sigma Investments first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2013 and held it in 14 quarters.
  • Two Sigma Investments's Viracta Therapeutics, Inc. Common Stock position peaked at $1.26M in Q3 2014.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Two Sigma Investments's 13F filing for Q2 2023, filed 14 Aug 2023.